



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

This document lists the medical benefit drugs that have authorization requirements for Blue Cross and Blue Shield Federal Employee Program non-Medicare members.

For dates of service on or after Dec. 1, 2020, providers will have to request authorization from Blue Cross Blue Shield of Michigan for some drugs covered under the medical benefit for Blue Cross and Blue Shield FEP non-Medicare members. Authorization will be required only when members receive the drugs in Michigan.

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J3262	Actemra®	tocilizumab	12/1/2020	12/1/2020
J2504	Adagen®	pegademase bovine	12/1/2020	12/1/2020
J1931	Aldurazyme®	laronidase	12/1/2020	12/1/2020
Q5126	Alymsys	Bevacizumab-maly	4/1/2024	
J0225	Amvuttra	vutrisiran	3/1/2024	
J0256	Aralast® NP	alpha 1 proteinase inhibitor	12/1/2020	12/1/2020
J1554	Asceniv®	immune globulin, human- slra	12/1/2020	12/1/2020
J9035, C9257	Avastin	Bevacizumab	4/1/2024	
J3145	Aveed®	testosterone undecanoate	12/1/2020	
Q5121	Avsola®	infliximab-axxq	1/1/2023	1/1/2023
J0490	Benlysta®	belimumab	12/1/2020	12/1/2020
J0179	Beovu®	brolocizumab-dbli	12/1/2020	
J0597	Beriner®	c1 esterase inhibitor	12/1/2020	12/1/2020
J1556	Bivigam®	immune globulin	12/1/2020	12/1/2020
J0585	Botox®	onabotulinumtoxina	12/1/2020	
J0567	Brineura®	cerliponase alfa	12/1/2020	
Q5124	Byooviz	ranibizumab-nuna	3/1/2024	



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J1566	Carimune® NF	immune globulin	12/1/2020	12/1/2020
J1786	Cerezyme®	imiglucerase	12/1/2020	12/1/2020
Q5128	Cimerli	ranibizumab-eqrn	3/1/2024	
J0717	Cimzia®	certolizumab pegol	12/1/2020	12/1/2020
J2786	Cinqair®	reslizumab	12/1/2020	12/1/2020
J0598	Cinryze®	c1 esterase inhibitor	12/1/2020	
J0584	Crysvita®	burosumab-twza	12/1/2020	12/1/2020
J1599	Cutaquig®	immune globulin	12/1/2020	12/1/2020
J1555	Cuvitru®	immune globulin	12/1/2020	12/1/2020
J0586	Dysport®	abobotulinumtoxina	12/1/2020	
J1743	Elaprase®	idursulfase	12/1/2020	12/1/2020
J3060	Elelyso®	taliglucerase alfa	12/1/2020	12/1/2020
J3380	Entyvio®	vedolizumab	12/1/2020	12/1/2020
J0885	Epogen	Epoetin Alfa	3/1/2024	
J3111	Evenity®	romosozumab-aqqg	12/1/2020	12/1/2020
J1428	Exondys® 51	eteplirsen	12/1/2020	
J0178	Eylea®	aflibercept	12/1/2020	
J3590, C9399	Eylea HD	aflibercept	3/1/2024	
J0180	Fabrazyme®	agalsidase beta	12/1/2020	12/1/2020
J0517	Fasenra®	benralizumab	12/1/2020	12/1/2020
J1572	Flebogamma® DIF	immune globulin	12/1/2020	12/1/2020
Q5108	Fulphila	Pegfilgrastim-jmdb	4/1/2024	
J0641	Fusilev®	levoleucovorin	12/1/2020	
Q5130	Fynetra	Pegfilgrastim-pbbk	4/1/2024	



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J1569	Gammagard®	immune globulin	12/1/2020	12/1/2020
J1566	Gammagard®S/D Less IgA	immune globulin	12/1/2020	12/1/2020
J1561	Gammaked®	immune globulin	12/1/2020	12/1/2020
J1557	Gammaplex®	immune globulin	12/1/2020	12/1/2020
J1561	Gamunex-C®	immune globulin	12/1/2020	12/1/2020
J0223	Givlaari	givosiran	3/1/2024	
J0257	Glassia®	alpha 1 proteinase inhibitor	12/1/2020	12/1/2020
J1447	Granix	tbo-Filgrastim	4/1/2024	
J7170	Hemlibra®	emicizumab-kxwh	12/1/2020	12/1/2020
J9355	Herceptin	Trastuzumab	4/1/2024	
J9356	Herceptin Hylecta	Trastuzumab and hyaluronidase-oysk	4/1/2024	
Q5113	Herzuma	Trastuzumab-pkrb	4/1/2024	
J1559	Hizentra®	immune globulin	12/1/2020	12/1/2020
J1726	Hydroxyprogesterone Caproate	hydroxyprogesterone caproate	12/1/2020	
J1729	Hydroxyprogesterone Caproate	hydroxyprogesterone caproate	12/1/2020	
J1575	Hyqvia®	immune globulin	12/1/2020	12/1/2020
J0638	Ilaris®	canakinumab	12/1/2020	12/1/2020
J3245	Ilumya®	tildrakizumab-asmn	12/1/2020	12/1/2020
Q5103	Inflectra®	infliximab-dyyb	12/1/2020	12/1/2020
J1745	Infliximab	infliximab	3/1/2024	3/1/2024
Q5109	Ixifi	infliximab-qbtx	3/1/2024	



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J1290	Kalbitor®	ecallantide	12/1/2020	12/1/2020
Q5117	Kanjinti	Trastuzumab-anns	4/1/2024	
J2840	Kanuma®	sebelipase alfa	12/1/2020	12/1/2020
J0642	Khapzory®	levoleucovorin	12/1/2020	
J2507	Krystexxa®	pegloticase	12/1/2020	12/1/2020
Q2042	Kymriah®	tisagenlecleucel	12/1/2020	
J0202	Lemtrada®	alemtuzumab	12/1/2020	12/1/2020
J0641	Levoleucovorin Calcium® PF	levoleucovorin	12/1/2020	
J2778	Lucentis®	ranibizumab	12/1/2020	
J0221	Lumizyme®	alglucosidase alfa	12/1/2020	12/1/2020
J3398	Luxturna®	voretigene neparvovec- rzyl	12/1/2020	
J2503	Macugen®	pegaptanib	12/1/2020	
J3397	Mepsevii®	vestronidase alfa-vjvk	12/1/2020	12/1/2020
Q5107	Mvasi	bevacizumab-awwb	4/1/2024	
J0587	Myobloc®	rimabotulinumtoxinb	12/1/2020	
J1458	Naglazyme®	galsulfase	12/1/2020	12/1/2020
J2506	Neulasta	Pegfilgrastim	4/1/2024	
J2506	Neulasta Onpro	Pegfilgrastim	4/1/2024	
J1442	Neupogen	Filgrastim	4/1/2024	
Q5110	Nivestym	Filgrastim-aafi	4/1/2024	
J2796	Nplate®	romiplostim	12/1/2020	
J2182	Nucala®	mepolizumab	12/1/2020	12/1/2020
Q5122	Nyvepria	Pegfilgrastim-apgf	4/1/2024	



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J2350	Ocrevus®	ocrelizumab	12/1/2020	12/1/2020
J1568	Octagam®	immune globulin	12/1/2020	12/1/2020
Q5114	Ogivri	Trastuzumab-dkst	4/1/2024	
J0222	Onpattro®	patisiran	12/1/2020	12/1/2020
Q5112	Ontruzant	Trastuzumab-dttb	4/1/2024	
J0129	Orencia®	abatacept	12/1/2020	12/1/2020
J0224	Oxlumo	lumarisan	3/1/2024	
J1599	Panzyga®	immune globulin, human - ifas	12/1/2020	12/1/2020
J1459	Privigen®	immune globulin	12/1/2020	12/1/2020
J0885	Procrit	epoetin alfa	3/1/2024	
J0256	Prolastin®-C	alpha 1 proteinase inhibitor	12/1/2020	12/1/2020
J0897	Prolia®	denosumab	12/1/2020	12/1/2020
J1301	Radicava®	edaravone	12/1/2020	12/1/2020
Q5125	Releuko	Filgrastim-ayow	4/1/2024	
J1745	Remicade®	infliximab	12/1/2020	12/1/2020
Q5104	Renflexis®	infliximab-abda	12/1/2020	12/1/2020
Q5106	Retacrit	Epoetin Alfa-Epbx	3/1/2024	
Q5123	Riabni	rituximab-arrx	3/1/2024	
J9312	Rituxan	rituximab	3/1/2024	
J9311	Rituxan Hycela	Rituximab - hyaluronidase human	4/1/2024	
J1449	Rolvedon	Hematopoietic - Eflapegrastim	4/1/2024	



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J0596	Ruconest®	c1 esterase inhibitor recombinant	12/1/2020	12/1/2020
Q5119	Ruxience	Rituximab-pvvr	3/1/2024	
J2327	Skyrizi IV	risankizumab-rzaa	3/1/2024	
J2502	Signifor® LAR	pasireotide long acting	12/1/2020	
J1602	Simponi Aria®	golimumab	12/1/2020	12/1/2020
J1300	Soliris®	eculizumab	12/1/2020	12/1/2020
J2326	Spinraza®	nusinersen	12/1/2020	
J3357	Stelara SQ	ustekinumab	3/1/2024	
J3358	Stelara®	ustekinumab	12/1/2020	12/1/2020
Q5127	Stimufend	Pegfilgrastim-fpgk	4/1/2024	
90378	Synagis®	palivizumab	12/1/2020	
J3490, J3590, C9399	Tegsedi	inotersen	3/1/2024	
S0189	Testopel®	testosterone pellets	12/1/2020	
Q5116	Trazimera	Trastuzumab-dttb	4/1/2024	
J1746	Trogarzo®	ibalizumab-uiyk	12/1/2020	12/1/2020
Q5115	Truxima	rituxamab -abbs	3/1/2024	
J2323	Tysabri®	natalizumab	12/1/2020	12/1/2020
Q5111	Udenyca	Pegfilgrastim-cbqv	4/1/2024	
J1303	Ultomiris®	ravulizumab-cwvz	12/1/2020	12/1/2020
J2777	Vabysmo	faricimab-svoa	3/1/2024	
Q5129	Vegzelma	Bevacizumab-adcd	4/1/2024	
J1322	Vimizim®	elosulfase alfa	12/1/2020	12/1/2020



A nonprofit corporation and independent licensee
of the Blue Cross and Blue Shield Association

Utilization management medical drug list

For Blue Cross and Blue Shield Federal Employee Program®
non-Medicare members

Effective Dec. 1, 2020

Revised Feb. 23, 2024

HCPCS code	Brand name	Generic name	Effective dates (If there's no date, there's no requirement)	
			Prior authorization	Site-of-care requirement
J3385	Vpriv®	velaglucerase alfa	12/1/2020	12/1/2020
J9332	Vyvgart	Efgartigimod alfa-fcab	3/1/2024	
J3590, C9399	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	3/1/2024	
J1558	Xembify®	immune globulin, human-klhw	12/1/2020	12/1/2020
J0588	Xeomin®	incobotulinumtoxina	12/1/2020	
J0897	Xgeva®	denosumab	12/1/2020	12/1/2020
J0775	Xiaflex®	collagenase clostridium histolyticum	12/1/2020	
J2357	Xolair®	omalizumab	12/1/2020	12/1/2020
Q2041	Yescarta®	axicabtagene ciloleucel	12/1/2020	
Q5101	Zarxio	Filgrastim-sndz	4/1/2024	
J0256	Zemaira®	alpha 1 proteinase inhibitor	12/1/2020	12/1/2020
Q5120	Ziextenzo	Pegfilgrastim-bmez	4/1/2024	
J3304	Zilretta®	triamcinolone acetone extended-release	12/1/2020	
Q5118	Zirabev	Bevacizumab-bvzr	4/1/2024	
J3399	Zolgensma®	onasemnogene abeparvovec-xioi	12/1/2020	